Infinity Pharma

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2021 financial results and provided corporate highlights. “Based on the strength and breadth of eganelisib's activity across mTNBC and mUC as well as ovarian cancer, SCCHN, and melanoma, we raised $92 million in early

Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, March 29th, 2022 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2021. Conference call & Webcast Details Date: Tuesday, March 29th Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com

Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 16th, 2022. 32nd Annual Oppenheimer Healthcare Conference (virtual) Date: March 16t

Infinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that it will be highlighted during a virtual oncology fireside chat with B. Riley biotech research analyst Kalpit Patel on Thursday, January 27th at 10:30 am ET. The fireside chat will feature an interactive discussion with Infinity's Executive Leadership Team,

Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley's 2022 Virtual Oncology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually. Conference details can be found below: J.P. Morgan Healt

Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today provided an update on eganelisib clinical development plans and 2022 guidance. “Eganelisib is a unique drug for which we have presented positive results in multiple indications where checkpoint inhibitors have provided little to no patient benefit. Based on these strong d

Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance

DatChat

Petros Pharmaceuticals

3 penny stocks investors decided to buy before next week. Are they on your list right now?

Best Penny Stocks To Buy Now? 3 To Watch Before Next Week

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021. The NBI is designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDA

Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that it will be highlighted during a “Best Ideas” virtual fireside chat with B. Riley Biotech research analyst Kalpit Patel on Tuesday, December 14th at 2:30 pm ET. The fireside

Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat

Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).  MARIO-3 Phase 2 trial is evaluating eganelisib in combination with Roche Holdings AG's (OTC: RHHBY) atezolizumab (Tecentriq) and Bristol-Myers Squibb Co's (NYSE: BMY) Abraxane (nab-paclitaxel) in frontline metastatic triple-negative breast cancer (TNBC).

Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today presented updated data from the ongoing MARIO-3 clinical study during the 2021 San Antonio Breast Cancer Symposium (SABCS). MARIO-3 is the Company's ongoing Phase 2 study evaluating eganelisib in combination with atezolizumab (Tecentriq®) and nab-paclitaxel (Abraxane®) in

Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that it will host an investor event on updated data from the ongoing MARIO-3 clinical study during the San Antonio Breast Cancer Symposium (SABCS 2021) on Friday, December 10th a

Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Infinity (INFI) Stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that Adelene Perkins, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation will be a fireside

Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q3 2021 Results - Earnings Call Transcript

Infinity (INFI) delivered earnings and revenue surprises of 14.29% and -5.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today announced its third quarter 2021 financial results and provided a corporate update on eganelisib, its potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic. “Infinity had a very successful 3rd quarter reaching major clinical milestones with eganelisib and welcoming two outstanding R&D executives to our management team,” said Adelene Perkins, C

Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, November 2nd 2021, at 4:30pm ET to report its financial results for the third quarter of 2021. Conference call & Webcast Details Date:

Infinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call and Webcast

An analyst initiated coverage of the biotech stock with a unambiguous buy recommendation.

Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will participate in Oppenheimer's Fall Healthcare Life Sciences and MedTech Summit and at the 3rd Annual Macrophage-directed Therapies Summit. Presenta

Infinity to Participate in Oppenheimer's Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer, today announced the appointment of Robert Ilaria, Jr., M.D. as Chief Medical Officer. In addition, Brian Schwartz, M.D., will be transitioning from his role as Consulting C

Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D.

Farmmi

Are these hot penny stocks on your watchlist right now? The post Hot Penny Stocks To Watch Making Big Moves This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Watch Making Big Moves This Week

Investors need to pay close attention to Infinity Pharmaceuticals (INFI) stock based on the movements in the options market lately.

Implied Volatility Surging for Infinity Pharmaceuticals (INFI) Stock Options

Atossa Genetics

Evofem Biosciences Inc

With biotech penny stocks heating up, here are 3 you need to know about in August The post Best Biotech Penny Stocks For Your Monday Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Infinity Pharma Stock (INFI)